NINGBO INNO PHARMCHEM CO.,LTD. is committed to supplying high-quality pharmaceutical intermediates that are crucial for the development of life-saving medications. Gefitinib, identified by its CAS number 184475-35-2, is a key compound in our offering, particularly vital for the synthesis of treatments for Non-Small Cell Lung Cancer (NSCLC). We understand the importance of reliable sourcing for this pharmaceutical intermediate to support the pharmaceutical industry's ongoing efforts.

The therapeutic efficacy of Gefitinib is rooted in its function as a protein kinase inhibitor. It specifically targets and blocks the activity of tyrosine kinases, such as the Epidermal Growth Factor Receptor (EGFR), which are critical drivers of cancer cell growth and survival in certain types of NSCLC. By inhibiting these pathways, Gefitinib offers a targeted and effective treatment option, improving patient prognosis.

The precise specifications of Gefitinib CAS 184475-35-2 as a pharmaceutical intermediate are essential for successful drug manufacturing. Its chemical name is N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine, with a molecular formula of C22H24ClFN4O3 and a molecular weight of 446.902. It is supplied as a white to beige powder, with a melting point of 119-120°C. NINGBO INNO PHARMCHEM CO.,LTD. ensures that our Gefitinib intermediate meets rigorous purity and quality standards, vital for consistent therapeutic outcomes.

It is important for medical professionals and researchers to be aware of the potential side effects associated with Gefitinib therapy, such as transient elevations in liver enzymes and, rarely, acute liver injury. This underscores the critical need for high-quality Gefitinib pharmaceutical intermediate in drug synthesis. By choosing NINGBO INNO PHARMCHEM CO.,LTD., manufacturers ensure the integrity of their final products, contributing to patient safety and treatment success.

In summary, Gefitinib CAS 184475-35-2 is an indispensable pharmaceutical intermediate for the development of targeted cancer therapies. Its role as a protein kinase inhibitor makes it a vital component in the fight against NSCLC. NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to providing this essential compound, thereby contributing to advancements in oncology and improving the lives of patients worldwide. Our commitment to quality and reliability makes us a trusted partner in the pharmaceutical supply chain.